NCCN Prostate Cancer Guidelines Review VL

NCCN Guidelines on Prostate Cancer Genetics - Christopher Wallis & Zachary Klaassen

Details
The UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen discuss the NCCN clinical practice guidelines in oncology focusing on prostate cancer genetics. To set the stage for discussing prostate cancer genetics, they start with a background on genetics and then focus on three specific aspects of prostate cancer genetics, namely homologous recombination repair, DNA mismatc...

NCCN Guidelines on Prostate Cancer - A Focus on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer - Christopher Wallis and Zachary Klaassen

Details
In this UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen, the pair continue their discussion on the NCCN clinical practice guidelines in oncology, with a focus on prostate cancer. This discussion is part two of a two-part series focusing on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer. For patients with metastatic castration-resistant...

NCCN Guidelines on Prostate Cancer: A Focus on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer - Chemotherapeutic Approaches - Christopher Wallis and Zachary Klaassen

Details
In this UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen, the pair continue their discussion on the NCCN clinical practice guidelines in oncology, with a focus on prostate cancer. This discussion is part one of a two-part series focusing on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer. For patients with metastatic castration-resistant...

Intermittent vs Continuous ADT for Patients A Review of the NCCN Guidelines – Christopher Wallis and Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen review the NCCN clinical practice guidelines on prostate cancer. This discussion is the third part of their discussion of androgen deprivation therapy (ADT). Dr. Wallis begins this discussion with a conversation on intermittent vs continuous ADT for patients with prostate cancer. He examines the quality of life in conjunction with survival measurements. Abou...

ADT for Castration-Naive Disease A Review of the NCCN Prostate Cancer Guidelines – Christopher Wallis and Zachary Klaassen

Details
In this UroToday discussion between Zachary Klaassen and Christopher Wallis, the pair discuss the NCCN clinical practice guidelines in oncology, specifically looking at prostate cancer. This part of the conversation specifically looks at androgen deprivation therapy (ADT) for castration-naive disease. Dr. Klaassen begins by discussing the different categories that ADT has been categorized into rec...

NCCN Guidelines on Prostate Cancer: A Focus on Castration-Resistant Prostate Cancer - Christopher Wallis and Zachary Klaassen

Details
Zachary Klaassen and Christopher Wallis discuss the NCCN guidelines for castration-resistant prostate cancer (CRPC) updated in February of 2021. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta U...

The NCCN Guidelines on Androgen Deprivation Therapy in Localized Disease, Regional Disease, and Palliative Treatment - Christopher Wallis and Zachary Klaassen

Details
UroToday is introducing an in-depth look at the NCCN Guidelines on Prostate Cancer. In this video presentation, Zachary Klaassen and Christopher Wallis focus on Androgen Deprivation Therapy (ADT), which is broken down into six subsections including ADT for clinically localized N0M0 disease, ADT for regional disease, palliative ADT, ADT for castration-naive disease, intermittent versus continuous A...